Phosphorylation of nucleoside analogs by equine herpesvirus type 1 pyrimidine deoxyribonucleoside kinase
- PMID: 3026247
- DOI: 10.1016/0166-3542(87)90039-8
Phosphorylation of nucleoside analogs by equine herpesvirus type 1 pyrimidine deoxyribonucleoside kinase
Abstract
Replication of equine herpesvirus type 1 (EHV-1) was sensitive to 9-(1,3-dihydroxy-2-propoxymethyl)guanine(DHPG) but relatively resistant to E-5-(2-bromovinyl)-2'-deoxyuridine (BVDU). Likewise, plaque formation by EHV-1 was inhibited by DHPG, but not by BVDU. Plaque formation by a thymidine kinase-negative (tk-) mutant of EHV-1 was not inhibited by DHPG. In order to investigate biochemical mechanisms determining the differential sensitivity of EHV-1 to these drugs, the EHV-1-encoded thymidine kinase enzyme activity (TK)1 was partially purified from EHV-1-infected cells and analyzed. The EHV-1-induced enzyme utilized both ATP and CTP as phosphate donors and differed in relative electrophoretic mobility from the TKs of mock-infected and HSV-1-infected cells. Phosphorylation of 3H-dThd by the EHV-1 TK was inhibited by AraT, IdUrd, BVDU, and DHPG. The EHV-1 TK phosphorylated 125I-dCyd and 3H-ACV. The results indicate that EHV-1 encodes a pyrimidine deoxyribonucleoside kinase with broad nucleoside substrate specificity. These observations suggest that the failure of BVDU to inhibit EHV-1 replication is not attributable to an inability of the EHV-1 TK to phosphorylate BVDU, but may result from the incapacity of the viral TK to convert BVDU monophosphate to the triphosphate or from lack of inhibitory effect of BVDU triphosphate on viral DNA polymerase reactions.
Similar articles
-
Differential metabolism of (E)-5-(2-iodovinyl)-2'-deoxyuridine (IVDU) by equine herpesvirus type 1- and herpes simplex virus-infected cells.Antiviral Res. 1987 Aug;8(1):41-51. doi: 10.1016/0166-3542(87)90086-6. Antiviral Res. 1987. PMID: 2825591
-
Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.Mol Pharmacol. 1987 Sep;32(3):410-6. Mol Pharmacol. 1987. PMID: 2823092
-
Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2.J Biol Chem. 1993 Mar 25;268(9):6332-7. J Biol Chem. 1993. PMID: 8384209
-
(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU).Med Res Rev. 2005 Jan;25(1):1-20. doi: 10.1002/med.20011. Med Res Rev. 2005. PMID: 15389733 Review.
-
The development of BVDU: An odyssey.Antivir Chem Chemother. 2023 Jan-Dec;31:20402066231152971. doi: 10.1177/20402066231152971. Antivir Chem Chemother. 2023. PMID: 36710501 Free PMC article. Review.
Cited by
-
Safety and efficacy of a thymidine kinase negative equine herpesvirus-1 vaccine in young horses.Can J Vet Res. 1990 Apr;54(2):260-6. Can J Vet Res. 1990. PMID: 2162730 Free PMC article.
-
Evolution of the herpes thymidine kinase: identification and comparison of the equine herpesvirus 1 thymidine kinase gene reveals similarity to a cell-encoded thymidylate kinase.Nucleic Acids Res. 1988 Dec 9;16(23):11303-17. doi: 10.1093/nar/16.23.11303. Nucleic Acids Res. 1988. PMID: 2849761 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources